Abstract
Non-alcoholic fatty liver disease (NAFLD) is commonly diagnosed in obese or overweight individuals. However, lean individuals with NAFLD represent one notable part of the phenotypic clinical cases of NAFLD. Current evidence suggests that lean and obese patients with NAFLD share different metabolic and cardiovascular disease (CVD) risk profiles. Lean NAFLD and its advanced form non-alcoholic steatohepatitis (NASH), need further investigation including epidemiology, clinical risk assessment, liver histological changes, genetic and pathophysiologic predisposing mechanisms, natural history, relation to CVD risk, and treatment strategies in this population with this under-recognized disease. However, to the extent it induces hepatic fibrosis (50% of the cases of NASH) this is as harmful as NAFLD in obese individuals and needs treatment with pioglitazone and potent statin for the reduction of liver and CVD morbidity and mortality.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
